A cost analysis of introducing an infectious disease specialist-guided antimicrobial stewardship in an area with relatively low prevalence of antimicrobial resistance

Peter Lanbeck¹, Gunnel Ragnarson Tennvall² and Fredrik Resman¹*

Abstract

Background: Antimicrobial stewardship programs have been widely introduced in hospitals as a response to increasing antimicrobial resistance. Although such programs are commonly used, the long-term effects on antimicrobial resistance as well as societal economics are uncertain.

Methods: We performed a cost analysis of an antimicrobial stewardship program introduced in Malmö, Sweden in 20 weeks 2013 compared with a corresponding control period in 2012. All direct costs and opportunity costs related to the stewardship intervention were calculated for both periods. Costs during the stewardship period were directly compared to costs in the control period and extrapolated to a yearly cost. Two main analyses were performed, one including only comparable direct costs (analysis one) and one including comparable direct and opportunity costs (analysis two). An extra analysis including all comparable direct costs including costs related to length of hospital stay (analysis three) was performed, but deemed as unrepresentative.

Results: According to analysis one, the cost per year was SEK 161 990 and in analysis two the cost per year was SEK 5 113. Since the two cohorts were skewed in terms of size and of infection severity as a consequence of the program, and since short-term patient outcomes have been demonstrated to be unchanged by the intervention, the costs pertaining to patient outcomes were not included in the analysis, and we suggest that analysis two provides the most correct cost calculation. In this analysis, the main cost drivers were the physician time and nursing time. A sensitivity analysis of analysis two suggested relatively modest variation under changing assumptions.

Conclusion: The total yearly cost of introducing an infectious disease specialist-guided, audit-based antimicrobial stewardship in a department of internal medicine, including direct costs and opportunity costs, was calculated to be as low as SEK 5 113.

Keywords: Economics, Costs, Antimicrobial stewardship, Antimicrobial resistance

* Correspondence: fredrik.resman@med.lu.se

¹Infectious Diseases Research Unit, Department of Clinical Sciences, Malmö, Lund University, Rut Lundskogs gata 3, plan 6, 20502 Malmö, Sweden

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

The emergence of antimicrobial resistance is described by the World Health Organization to be “an increasingly serious threat to global public health that requires action across all government sectors and society” [1]. Several factors contribute to the spread of antimicrobial resistance in the community. The misuse or overuse of antibiotics in human medicine is one such factor, and possibly the factor that has been discussed and addressed the most [2].

The term ‘Antimicrobial stewardship programs’ (ASPs) is an umbrella definition that in practice may encompass several different measures. ASPs have been introduced widely to address the misuse of antibiotics in human medicine [3, 4], and hospital programs may include restrictive measures as well as persuasive interventions including audit and feedback methodology [5]. There is no consensus on what outcomes should be monitored when an ASP is launched, and opinions on what outcomes are most important vary from different perspectives [6]. Unfortunately, there is still no conclusive evidence that a reduction of antibiotic use results in reduced antimicrobial resistance [7]. Due to these uncertainties, it is important to monitor individual patient outcomes during the launch of antimicrobial stewardship programs to make sure that programs do not introduce harm. We also believe that it is necessary to analyse the economic consequences of ASPs, to make sure that decisions to introduce ASPs can be objectively compared with other potential efforts.

The full health-economic consequences of antimicrobial stewardship programs are complex to calculate due to uncertainties in long-term effects on costs and benefits, as well as due to uncertainties in attributable costs and effects of the infection. Recently, systematic approaches to address such health economic evaluations have been suggested [8]. Besides the implementation costs and operational costs of the program itself, it is necessary to include the direct costs of antibiotics, including time for handling and materials as well as costs related to patients outcomes, normally hospital lengths-of-stay. It would be desirable to include a calculation of the societal effects, but such calculations are at best uncertain.

In this investigation, the aim was to study the economic consequences of introducing an individual audit-based ASP in Sweden, a region with a limited prior history of systematic ASPs. The program has been demonstrated to be successful in substantially reducing antibiotic use and maintaining favourable patient outcomes [9]. However, since individual audit and feedback-based programs are generally considered as cost-intensive, and since alternative ways of performing stewardship interventions exist, a follow-up cost analysis was deemed valuable. The rates of Clostridium difficile-associated disease (80 cases per 100,000 individuals) [10] as well as the rates of carriage of resistant bacteria [11] are comparatively low in Sweden, with rates of E. coli with extended-spectrum betalactamase production at 5% and rates of methicillin-resistant isolates among Staphylococcus aureus at around 1%. Since this particular program was introduced during ‘normal’ circumstances, i.e. not in response to an outbreak of resistant bacteria or Clostridium difficile, we believe that the results can be generalizable to other regions with low proportions of antimicrobial resistance.

Methods

Study setting

The original study [9] was performed in the Department of Internal Medicine, Malmö at Skåne University Hospital in Sweden, a hospital with approximately 1100 beds at two sites. The department is a secondary care unit serving patients in general internal medicine, including mainly elderly patients with one or more chronic underlying condition. The geographical area that the hospital serves has a population of approximately 700 000.

The antibiotic stewardship intervention study design

This cost analysis is based on a quasi-experimental trial with an historic control of the introduction of an antibiotic stewardship intervention. The intervention was performed in four wards of internal medicine, from April 1 through June 20, 2013 as well as August 26 through October 21, 2013. Considering the variability of influenza seasons, the intervention was not performed during influenza seasons. All patients that received, or were prescribed, antibiotics were audited by an infectious disease-specialist twice weekly. The control group consisted of individuals treated with antibiotics during admission to the same wards in the corresponding time period 2012, when no active intervention was in place. An ATC-code based search of the computerized medical records unambiguously identified all cases that had received antibiotics in the two periods, audited or not. Patients receiving antibiotic prophylaxis only were excluded from the analysis [9]. All audits were performed as real-time discussions, including feedback, between the auditing ID specialist and the ward physician. Discussions concerning approximately 25–30 patients took place on each audit day. In some instances, a brief renewed physical examination was performed. All patients with antibiotics were discussed on each occasion, even though the same patient had been discussed in prior visits. Since the ward doctors generally were responsible for a third of patients in a ward, the time spent for each doctor in the ward was approximately 15–20 min per occasion (the four wards had separate medical staff), including write-ups. Even though the patients
in the original study were not randomized, they were well-balanced with regards to age, gender and underlying diseases [9].

**Definition of resource categories and unit costs**

The present cost analysis is based on the results from the antimicrobial stewardship program that was introduced in the department of internal medicine in southern Sweden in 2013. The clinical aspects of the study have been evaluated and published. This cost analysis is based on the same data [9].

Resource utilization was estimated for audits four hours per time twice weekly for both the specialist physician from the department of infectious diseases and a physician from the study wards. Resource utilization for nurses was estimated based on an assumption about 18 min for preparation and distribution of each dose of IV antibiotics to the patients (the time was based on an inquiry performed at hospital wards) and 6 total minutes per day for administration of each oral antibiotic (normally two to three doses per day).

The implementation costs of the program were based on the time needed to plan the project and provide written and oral information of the project to colleagues to the involved staff. Costs for physicians were calculated based on information from the Swedish Medical association 2015 [12], while the costs for nurses were calculated based on information from Statistics Sweden regarding average salaries in 2014 for professionals in health care [13]. Wages were adjusted to 2015 price level with a labour cost index from Statistics Sweden for employees in the sector of human health and social work activities [14]. A payroll tax for county councils of 41% was added [15]. Even though the actual audits at the wards could sometimes be performed in less than four hours, though not measured to the minute, costs were based on four-hour audits on each of the forty audits to apply the most conservative cost estimate.

Antibiotic costs were calculated from official price lists in all cases except for ampicillin where information was collected through personal communication with an administration staff in the Southern health care region. For IV antibiotics a daily cost was estimated based on average doses in the medical charts and unit prices from a local database. This database includes information about drugs where the price has been negotiated between pharmaceutical companies and the Southern health care region [16]. Similarly, the cost of oral antibiotics was estimated from the average doses in the medical charts and unit prices from FASS [17]. Whereas all IV antibiotics were given in the wards, the proportion of oral antibiotics given in the wards was calculated in order to apply nurse preparation costs only for in-hospital treatment.

Material costs for administration of IV treatment were estimated for syringes, needles, peripheral venous catheter, liquids (sodium chloride or sterile water), etc. at SEK15.70. An assumption was made that peripheral venous catheters were changed every fourth day [18].

Indirect cost for production losses are not included since the median age of patients was 83 years [9]. All costs are expressed in SEK in 2015 price level. Unit costs used in the calculations are presented in Table 1. The average exchange rate in 2015 was 1 USD = SEK 8.435 and 1 EUR = SEK 9.356 [19].

**Table 1** Unit costs of each resource category (in SEK, 2015 price level)

| Type of resource                                      | Unit cost Source | Source |
|-------------------------------------------------------|------------------|--------|
| Implementation cost (one-time cost)                   | 13 620.00        | Estimated |
| Hospital stay department of internal medicine (per day)| 4 643.00         | [26]    |
| Audit with specialist in infectious diseases (per four hours) | 2 348.00         | [12, 15]| |
| Resident physician in internal medicine (per four hours) | 1 536.00         | [12, 15]| |
| Materials used per dose of IV treatment               | 15.70            | Assumption |
| Nurse time (18 min per dose of IV treatment)           | 95.22            | Assumption and [13–15] |
| Nurse time (6 min per day for oral antibiotics)        | 31.72            | Assumption and [13–15] |
| IV antibiotics (average cost per day)                  |                  |        |
| - cefotaxim                                           | 23.18            | [16]    |
| - bensylpenicillin                                    | 36.00            | [16]    |
| - cloxacillin                                         | 39.90            | [16]    |
| - ampicillin                                          | 252.00           | Personal communication |
| - piperacillin-tazobactam                             | 43.50            | [16]    |
| - imipenem                                            | 83.25            | [16]    |
| - meropenem                                           | 71.70            | [16]    |
| Oral antibiotics (average cost per day)                |                  |        |
| - phenoxyxymethypenicillin                            | 7.11             | [17]    |
| - amoxicillin                                         | 3.15             | [17]    |
| - amoxicillin-calvulanate                             | 15.30            | [17]    |
| - dicloxacillin                                       | 19.62            | [17]    |
| - ciprofloxacin                                       | 5.20             | [17]    |
| - trimethoprim-sulfamethoxazole                       | 5.65             | [17]    |
| - tetracycline                                        | 8.35             | [17]    |
| - clindamycin                                         | 14.73            | [17]    |
| - metronidazole                                       | 7.10             | [17]    |
| - nitrofurantoin                                      | 3.51             | [17]    |
| - pivmecillinam                                       | 23.05            | [17]    |
Data analysis

The antimicrobial stewardship program was implemented during five months. The costs for the program was calculated for these five months and then extrapolated to one whole year, with the exception of the implementation cost. This extrapolation may not reflect a true yearly cost as monthly costs, as well as effect sizes may be reduced during a longer course of a program. All costs were estimated for two periods, one period when the stewardship program was implemented (2013) and one control period (2012).

Three analyses of costs comparisons were performed (Additional file 1: Table S1). Direct costs for project implementation, for each antibiotic (including material costs) and for utilization of infectious disease physician time were specifically allocated to the project and directly comparable between the two periods. A comparison between the intervention period and control period was made including only these direct costs. This was designated analysis one. Costs for nurse time (for preparation and administration of antibiotics) and ward physician time are opportunity costs not specifically allocated to the project, but directly comparable between the two projects. Opportunity costs in this specific setting means that the nurses and doctors can potentially be freed and be available for other tasks. A second comparison, analysis two, was performed including these costs. The direct costs for hospital-lengths of stay for patients treated with antibiotics in each period were included in analysis three. However, since fewer individuals were started on antibiotics during the stewardship intervention and since there were no statistically significant differences in patient length-of-stay between the two periods [9], it can be debated whether the periods can be considered directly comparable with regards to total lengths of hospital stay. The same reasoning applies to mortality and readmission, as even though the absolute numbers were lower during the stewardship intervention the proportions were the same, and no significant differences in 28-day mortality or 28-day readmissions between the two periods were demonstrated in the original report [9]. Our view as that an inclusion of these outcome terms in the direct cost analysis would not be meaningful, but rather skew the costs in favour of the intervention. Thus, data on mortality and on readmissions were presented (Table 2) but not included in the cost analyses. An attempt to address the indirect or societal costs of the program was not performed.

Sensitivity analyses were performed to evaluate the robustness of the base case results for analysis two by varying the most important cost drivers; physician time and nursing time. In addition, the material costs for preparation of IV antibiotics were varied between SEK14 and SEK18 instead of SEK15.70 from the base case analysis. The weekly time for physician audits was varied from eight hours weekly to six hours per week. Nurse time for administration of IV antibiotics was varied between 16 and 20 min per preparation instead of 18 min as in the base case while the time for administration of oral antibiotics was varied between 4 and 8 min instead of 6 min. The sensitivity analyses were confined to analysis two.

### Table 2 Unit or days of utilization per resource category and study period (costs in SEK, 2015 price level)

| Type of resource/cost unit | Total number of days/units during stewardship intervention 2013 | Total number of days/units during control period 2012 |
|---------------------------|---------------------------------------------------------------|-----------------------------------------------------|
| Implementation cost (units) | 1                                                             | 0                                                   |
| Hospital stay (days)       | 7193                                                          | 7402                                                |
| ID specialist time (units) | 40                                                            | 0                                                   |
| Resident physician time (units) | 40                                                          | 0                                                   |
| IV antibiotic treatment, materials (doses) | 6472                                                          | 7251                                                |
| IV antibiotic treatment, nurse time (doses) | 6472                                                          | 7251                                                |
| Hospital oral antibiotic treatment, nurse time (days) | 1477                                                          | 2975                                                |
| Cefotaxim                  | 1373                                                          | 1882                                                |
| bensylpenicillin           | 423                                                           | 394                                                 |
| cloxacillin                | 226                                                           | 202                                                 |
|ampicillin                  | 6                                                             | 5                                                   |
| piperacillin-tazobactam    | 270                                                           | 206                                                 |
| meropenem                  | 35                                                            | 68                                                  |
| phenoxyxymethyl-penicillin | 810                                                           | 789                                                 |
| Amoxicillin                | 1109                                                          | 1638                                                |
| dicloxacillin              | 270                                                           | 300                                                 |
| Ciprofloxacin              | 534                                                           | 1110                                                |
| trimethoprim-sulfamethoxazole | 489                                                          | 557                                                 |
| Tetracycline               | 409                                                           | 794                                                 |
| Clindamycin                | 219                                                           | 462                                                 |
| metronidazol               | 255                                                           | 221                                                 |
| Nitrofurantoin             | 86                                                            | 150                                                 |
| Pivmecillinam              | 283                                                           | 427                                                 |
| Death within 28 days (no. of patients) | 108                                                          | 117                                                 |
| Readmission within 28 days (no. of patients) | 180                                                          | 203                                                 |

*All antibiotic costs are in full days
Results

Cost units during the stewardship and the control period
The implementation process of the program itself demanded 20 h of Infectious Diseases specialist physician time. The total hospital length of stay for all patients was 7,193 days for the stewardship period and 7,402 days for the control period. The total days of oral treatment that were given in-hospital in each cohort was calculated to be 1,477 in the stewardship cohort and 2,975 in the control cohort. Resource utilization for each cost unit and cohort is presented in Table 2.

Total cost of each unit of the implementation of an antimicrobial stewardship program
For each resource category, the total cost per cohort and the overall balance is presented in Table 3. A negative balance in a resource category implies that the stewardship intervention leads to cost-savings in the actual category. Categories where substantial savings occurred as a result of the stewardship program include the cost of nurse time for administration of IV and oral antibiotics and the material costs of IV antibiotics. Moderate cost-savings were found in several categories of antibiotics (Table 3).

The cost analyses of implementation of the stewardship program
In analysis one, only direct and comparable costs specifically allocated to the stewardship program were included (for resource categories included, see Table 3). In this analysis, the extrapolated yearly cost of the stewardship program was SEK 161,990 (approximately USD 19,205 and EUR 17,313).

In analysis two, direct and comparable costs as well as comparable opportunity costs were included. This allowed the addition of the cost of ward staff time in

| Type of resource/cost unit                  | Cost during the stewardship intervention | Cost during the control period | Total balance per resource | Included in analysis |
|--------------------------------------------|------------------------------------------|--------------------------------|----------------------------|----------------------|
| Implementation cost                        | 13,620                                   | 0                              | 13,620                     | 1,2,3                |
| Hospital stay                              | 33,397 099                               | 34,367 486                     | −970 387                   | 3                    |
| ID specialist time                         | 93 920                                   | 0                              | 93 920                     | 1,2,3                |
| Resident physician time                    | 61 440                                   | 0                              | 61 440                     | 2,3                  |
| IV antibiotic treatment, materials         | 101 610                                  | 113 841                        | −12 230                    | 1,2,3                |
| IV antibiotic treatment, nurse time        | 616 264                                  | 690 440                        | −74 176                    | 2,3                  |
| Oral antibiotic treatment, nurse time      | 46 850                                   | 94 367                         | −47 517                    | 2,3                  |
| cefotaxin                                  | 31 826                                   | 43 625                         | −11 799                    | 1,2,3                |
| benzylenicillin                            | 15 228                                   | 14 184                         | 1 044                      | 1,2,3                |
| cloxacillin                                | 9 017                                    | 8 059                          | 958                        | 1,2,3                |
| ampicillin                                 | 1 512                                    | 1 260                          | 252                        | 1,2,3                |
| piperacillin-tazobactam                    | 11 745                                   | 8 961                          | 2 784                      | 1,2,3                |
| meropenem                                  | 2 510                                    | 4 876                          | −2 366                     | 1,2,3                |
| phenoxymethyl- penicillin                  | 5 759                                    | 5 610                          | 149                        | 1,2,3                |
| amoxicillin                                | 3 493                                    | 5 159                          | −1 666                     | 1,2,3                |
| dicloxacillin                              | 5 298                                    | 5 886                          | −588                       | 1,2,3                |
| ciprofloxacin                              | 2 777                                    | 5 772                          | −2 995                     | 1,2,3                |
| trimethoprim-sulfamethoxazole              | 2 763                                    | 3 147                          | −384                       | 1,2,3                |
| tetracycline                               | 3 415                                    | 6 630                          | −3 215                     | 1,2,3                |
| clindamycin                                | 3 226                                    | 6 805                          | −3 579                     | 1,2,3                |
| metronidazol                               | 1 810                                    | 1 569                          | 241                        | 1,2,3                |
| nitrofurantoin                             | 302                                      | 527                            | −225                       | 1,2,3                |
| pivmecillinam                              | 6 523                                    | 9 842                          | −3 319                     | 1,2,3                |
| Analysis one (yearly cost)                 | 800 948                                  | 638 958                        | 161 990                    |                       |
| Analysis two (yearly cost)                 | 2 684 569                                | 2 679 456                      | 5 113                      |                       |
| Analysis three (yearly cost)               | (89 517 026)                             | (92 034 920)                   | (−2 517 894)               |                       |

*The implementation cost was a one-time cost, and was not extrapolated in the yearly calculation*
the evaluation (for included resource categories, see Table 3). In this analysis, the extrapolated yearly cost of the stewardship program was SEK 5 113 (approximately USD 606 and EUR 546).

In analysis three, direct and comparable costs, comparable opportunity costs as well as the costs from the hospital lengths of stay of patients treated with antibiotics were included (for included resource categories, see Table 3). In this analysis, the intervention lead to a lowering of costs, and the extrapolated yearly saving of the stewardship was SEK 2 517 894 (approximately USD 298 506 and EUR 269 115).

The results from the sensitivity analyses are presented in Table 4. Variations on assumptions of the main cost drivers: physician time, nurse time and material costs for analysis two resulted in a total range from cost reduction of SEK 153 574 to a maximum cost of SEK 76 734.

**Discussion**

Our antimicrobial stewardship was conducted using an individual audit and direct feedback system involving infectious disease specialists, which would be considered a costly variant. It was introduced among a geriatric patient group mainly prescribed low-cost antibiotics in a setting with no on-going outbreak and low general levels of antimicrobial resistance. Despite this, the project almost fully bears its own costs (an extrapolated yearly cost of SEK 5 113 or USD 606) when a conservative approach was performed, including all comparable direct and opportunity costs objectively attributed to the intervention (analysis two). This analysis neither includes costs of the beneficial patient outcomes (including length of stay in hospital), nor the potential long-term societal benefits of reducing antibiotic misuse/overuse.

The strengths of this study include an individual characterization and follow-up of each patient receiving antibiotics during the intervention and control period, allowing a detailed, correct and comparable economic analysis. Another strength is that the study was conducted with no on-going outbreak, reducing the risks of overestimating the effects and providing more generalizable results. The limitations include the limited follow-up time of the intervention and the quasi-experimental (before-after) design. Another potential limitation is that a follow-up only was performed on patients that actually received antibiotics and not all patients in the ward. Fewer patients in total were started on antibiotics during the intervention, and there was a selection towards more severe infections during the stewardship intervention. This was indicated by significantly higher levels of C-reactive protein (CRP) and a significant reduction in antibiotics only used for less severe infections, such as cystitis, during the intervention [9]. The direct costs related to short-term outcomes such as mortality and readmission were thus not directly comparable between the two cohorts, but would rather skew the cost analysis in favour of the intervention, even though they have been demonstrated using statistical analysis of the proportions to be unchanged following the intervention [9].

In the present work, we have applied three different cost analyses. Whenever they are possible to calculate, it is suggested to include all opportunity costs in the analysis of total antimicrobial stewardship costs [8]. Therefore, we argue that analysis one does not provide enough information to be used. Normally, it is suggested that the total costs related to lengths-of-stay also should be included in the analysis of each cohort, which is performed in analysis three. However, since only patients started on antibiotics are included in our analysis, and since the severities of the infections treated with antibiotics in the two periods differ, the two cohorts are difficult to compare with respect to outcomes including hospital lengths-of stay. Also, the fact that fewer hospitalized patients receive antibiotics will not mean that there are fewer patients in the ward, and will not mean a cost reduction for the ward in absolute terms. Due to these concerns, we believe that analysis three is of least value and is put in parenthesis. Our belief is that the most objective analysis is analysis two. We performed a sensitivity analysis of the costs in analysis two, suggesting that there is uncertainty depending on the assumptions made, but that the variation is below 10% of the total cost.

**Table 4** Results of base case and sensitivity analyses of analysis two, yearly cost (in SEK, 2015 price level)

| Type of resource/cost unit | Cost during the stewardship intervention | Cost during the control period | Balance   |
|----------------------------|------------------------------------------|--------------------------------|-----------|
| Base case analysis two     | 2 684 569                                | 2 679 456                      | 5 113     |
| Physician time 6 h per week | 2 583 585                                | 2 679 456                      | -95 871   |
| Nurse time 16 min for IV antibiotics and 4 min for oral antibiotics | 2 465 934                              | 2 398 211                      | 67 723    |
| Nurse time 20 min for IV antibiotics and 8 min for oral antibiotics | 2 903 205                              | 2 960 908                      | -57 703   |
| Material cost IV administration SEK14 | 2 655 963                              | 2 647 407                      | 8 556     |
| Material cost IV administration SEK18 | 2 723 272                              | 2 722 817                      | 455       |
Even though guidelines have been formulated [20], antimicrobial stewardships can be conducted in several different ways, and these decisions clearly have implications for the economic consequences of the program. There have been a number of examples of stewardship interventions with distinct cost reductions as a consequence [21]. Most of these programs have been conducted in areas with high proportions of antimicrobial resistance and use of high-cost antibiotics. Most cost-saving interventions that were not conducted in such areas have other distinctions; including mainly younger patients [18], a focus on specific problem pathogens [22] or on diagnostic interventions [23]. We believe that the results of our stewardship program, targeting mainly elderly hospitalized patients with underlying diseases in a setting with low rates of antimicrobial resistance and not in response to an outbreak, can be generalizable to hospitals in regions with corresponding levels of antimicrobial resistance. This would be especially true in areas with corresponding population demographics. We also believe that it is probable that such a program would work well in a setting with higher levels of antimicrobial resistance. Also, the use of individual audits between an ID-specialist and a ward physician likely provides substantial secondary gains that are not measurable. There is evidence that ID-specialists can improve patient outcomes and induce cost savings [24], but some of the most important consequences of our program have been the bilateral knowledge gain from interdisciplinary discussions. Even though a total of 8 h of ID physician time per week were spent on the stewardship intervention, this cost analysis demonstrates that the cost of the program is comparatively low.

Conclusions
The cost analysis provided in this study shows that an audit-based individual antimicrobial stewardship can bear its own costs, even in a situation with low general levels of antimicrobial resistance. The results show that such programs can be performed at a relatively low cost also in regions with lower proportions of antimicrobial resistance. However, to combat antimicrobial resistance on a larger scale, a multitude of simultaneous measures are needed, tailored to each specific setting [25].

Acknowledgements
We would like to acknowledge all patients and physicians that have consented to be a part of the original study.

Funding
This work was supported by Skåne University Hospital, Skåne regional council and in part by funds from the agreement concerning research and education of doctors.

Availability of data and materials
All anonymous data that the calculations in the manuscript rely upon are presented in the tables. The original database has personal identifiers and is not appropriate to publicly share.

Authors’ contributions
This study was conceived and planned by PL and FR. The data analysis was performed by GRT and FR. The manuscript was written and reviewed by all authors. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interest.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The original study was approved by the regional ethical Review Board in Lund, Sweden (2013/115). No further ethical approval was deemed necessary for this economic analysis.

Author details
1 Infectious Diseases Research Unit, Department of Clinical Sciences, Malmö, Lund University, Rut Lunds kogs gata 3, plan 6, 20502 Malin, Sweden. T HE, The Swedish Institute for Health Economics, PO Box 21275 E-220 02 Lund, Sweden.

Received: 19 January 2016 Accepted: 20 July 2016
Published online: 27 July 2016

References
1. WHO. Antimicrobial resistance Fact sheet No. 194 who homepage: World Health Organization; 2015 [updated May 2015; cited 2016 January 4th]. Fact sheet. Available from: http://www.who.int/mediacentre/factsheets/fs194/en/.
2. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Srinath S, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–98.
3. Johansson B, Beekmann SE, Srinkasan A, Hersh AL, Laxminarayan R, Polgreen PM. Improving antimicrobial stewardship: the evolution of programmatic strategies and barriers. Infect Control Hosp Epidemiol. 2011;32(4):367–74.
4. Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis. 2013;56(10):1445–50.
5. Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. The Cochrane database of systematic reviews. 2013;4:CD003543.
6. Bumpass JB, McDanel PM, DePestel DD, Lamp KC, Chung TJ, McKinnon PS, et al. Outcomes and metrics for antimicrobial stewardship: survey of physicians and pharmacists. Clin Infect Dis. 2014;59 Suppl 3:S108–11.
7. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176–87.
8. Dík JW, Vemer P, Friedrich AW, Hendrix R, Lo-Ten-Foe JR, Sinha B, et al. Financial evaluations of antibiotic stewardship programs-a systematic review. Front Microbiol. 2015;6:317. Pubmed Central PMCID: 4399335.
9. Nilholm H, Holmstrand L, Ahl J, Mansson F, Odenthoit I, Tham J, et al. An audit-based, infectious disease specialist-guided antimicrobial stewardship program profoundly reduced antibiotic use without negatively affecting patient outcomes. Open forum infectious diseases. 2015;2(2):ofv042. Pubmed Central PMCID: 4567088.
10. Folkhälsoombudshuset. Clostridium difficile årsrapport 2014 [pdf file]. webpage of folkhälsoombudshuset2015 [cited 2016 february 7th 2016].

Additional file

Additional file 1: Table S1. Analyses in the dataset (DOCX 47 kb)

Abbreviations
ASP, antimicrobial stewardship program; ATC, Anatomical therapeutic chemical classification; EUR, Euro; FASS, Farmaceutiska specialister i Sverige (Pharmaceutical specialties in Sweden); ID, infectious diseases; IV, intravenous; SEK, Svensk krona (Swedish crown currency); USD, US dollar
2014 [yearly report]. Available from: http://www.folkhalsomyndigheten.se/publicerat-material/publikationer/clostridium-difficile-arsrapport-2014/.
11. Folkhälsomyndigheten. Sweden’s i korhett: folkhälsomyndigheten; 2015 [cited 2016 May 2nd]. Short description of the epidemiology of antimicrobial resistance in Sweden 2014. Available from: https://www.folkhalsomyndigheten.se/publicerat-material/publikationer/Swedres-i-korhett-2014/.
12. Association SM. SACO Lönssök: SACO/SLF; 2015 [cited 2016 January 13th]. Web page. Available from: http://www.saco.se/studieval-karriar/pa-jobbet/sa-satts-din-lon/saco-lonesok/.
13. Statistics Sweden. Statistics database, labour market, wage and salary structures and employment in county councils, salaries. 2015. Assessed at http://www.statistikdatabasen.scb.se/pxweb/sv/ssd/START__AM__AM0105__AM0105A/?rxid=45f16c0d-3773-46a1-a3f4-b537b3020616.
14. Statistics Sweden. Labour cost index for employees in the sector of human health and social work activities. 2015. Assessed at http://www.scb.se/en_/Finding-statistics/Statistics-by-subject-area/Labour-market/Wages-salaries-and-labour-costs/Labour-cost-index-for-wage-earners-and-salaried-employees-in-the-private-sector-AK1/Aktuell-Pong/7974/23106/.
15. Swedish Association of Local Authorities and Regions. Arbetsgivaravgifter för landsting år 2015. 2015. Assessed at http://sln.se/ekonomijuridikstatistik/ekonom/budgetochplanering/arbetsgivaravgifter.1290.html.
16. Region Skåne. Avtalad lista 2015. 2015. Assessed at http://www.skane.se/Public/PA/Lakemedel_alla.xlsx.
17. FASS Pharmaceutical Specialities in Sweden 2015. (Assessed at http://www.fass.se). 2015.
18. Dik JW, Hendrix R, Friedrich AW, Luttijoer J, Panday PN, Witting KR, et al. Cost-minimization model of a multidisciplinary antibiotic stewardship team based on a successful implementation on a urology ward of an academic hospital. PLoS One. 2015;10(5):e0126106. Pubmed Central PMCID: 4425554.
19. Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious diseases society of america and the society for healthcare epidemiology of america guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–77.
20. Goff DA. Antimicrobial stewardship: bridging the gap between quality care and cost. Curr Opin Infect Dis. 2011;24 Suppl 1:151–20.
21. Chow M, Carmeli Y, Shkim P, Elhayany A, Geffen K. Cost analysis of an intervention to prevent methicillin-resistant staphylococcus aureus (MRSA) transmission. PLoS One. 2015;10(9):e0138999. Pubmed Central PMCID: 4583443.
22. Bauer KA, West JE, Balada-Ulas JM, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program’s impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis. 2010;51(9):1074–80.
23. McQuillen DP, Petrou RM, Wasserman RB, Nahass RG, Scull JA, Martellini LP. The value of infectious diseases specialists: non-patient care activities. Clin Infect Dis. 2008;47(8):1051–63.
24. Nathan C, Cars O. Antibiotic resistance–problems, progress, and prospects. N Engl J Med. 2014;371(19):1761–3.
25. Southern Regional Health Care Committee. Regional prices and payments for the Southern Healthcare Region in 2015. [Regionala priser och ersättningar för Södra Sjukvårdsregionen 2015] (Assessed at http://www.skane.se/).